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Safety and Immunogenicity of Pneumococcal Conjugate 
Vaccines in a High-risk Population: A Randomized 
Controlled Trial of 10-Valent and 13-Valent Pneumococcal 
Conjugate Vaccine in Papua New Guinean Infants
William S. Pomat,1,a Anita H.J. van den Biggelaar,2,a,  Sandra Wana,1 Jacinta P. Francis,1 Vela Solomon,1 Andrew R. Greenhill,1,3 Rebecca Ford,1 
Tilda Orami,1 Megan Passey,4 Peter Jacoby,5 Lea-Ann Kirkham,2,6 Deborah Lehmann,2,b and Peter C. Richmond2,7,b; and the 10v13v PCV Trial Team
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Lismore, New South Wales, and 5Department of Biostatistics, Telethon Kids Institute and Centre for Child Health Research, 6School of Biomedical Sciences, and 7Division of Paediatrics and Child 
Health, School of Medicine, University of Western Australia, Perth
Background. There are little data on the immunogenicity of PCV10 and PCV13 in the same high-risk population.
Methods. PCV10 and PCV13 were studied head-to-head in a randomized controlled trial in Papua New Guinea in which 262 
infants received 3 doses of PCV10 or PCV13 at 1, 2, and 3 months of age. Serotype-specific immunoglobulin G (IgG) concentrations, 
and pneumococcal and nontypeable Haemophilus influenzae (NTHi) carriage were assessed prevaccination and at 4 and 9 months 
of age. Infants were followed up for safety until 9 months of age.
Results. One month after the third dose of PCV10 or PCV13, ˃80% of infants had IgG concentrations ≥0.35µg/mL for vaccine 
serotypes, and 6 months postvaccination IgG concentrations ≥0.35 µg/mL were maintained for 8/10 shared PCV serotypes in > 75% 
of children vaccinated with either PCV10 or PCV13. Children carried a total of 65 different pneumococcal serotypes (plus nonse-
rotypeable). At 4 months of age, 92% (95% confidence interval [CI] 85–96) of children vaccinated with PCV10 and 81% (95% CI 
72–88) vaccinated with PCV13 were pneumococcal carriers (P = .023), whereas no differences were seen at 9 months of age, or for 
NTHi carriage. Both vaccines were well tolerated and not associated with serious adverse events.
Conclusions. Infant vaccination with 3 doses of PCV10 or PCV13 is safe and immunogenic in a highly endemic setting; how-
ever, to significantly reduce pneumococcal disease in these settings, PCVs with broader serotype coverage and potency to reduce 
pneumococcal carriage are needed.
Clinical Trials Registration. NCT01619462.
Keywords. pneumococcal conjugate vaccine; S. pneumonia; antibodies; carriage; Papua New Guinea.
 The global implementation of pneumococcal conjugate vac-
cine (PCV) in childhood immunization programs has been 
faster than for any other vaccine in the past, reaching an esti-
mated global coverage of 42% in 2016 [1] and has prevented an 
estimated 230 000 to 290 000 pneumococcal deaths in children 
under 5 years of age in low-income countries between 2009 and 
2015 [2]. Still, many infants are not being vaccinated against 
pneumococcal infections. Although supply shortages have 
delayed PCV introduction in many countries [2], other coun-
tries are yet to decide on implementing PCV and which vaccine 
to choose.
Currently, 10-valent (PCV10) and 13-valent (PCV13) vac-
cines are licensed for immunization of infants. These vaccines 
differ in composition: PCV13 covers 3 additional serotypes 
compared to PCV10, whereas PCV10 contains a nontypeable 
Haemophilus influenzae (NTHi) Protein D carrier [3–5]. Both 
vaccines are effective in preventing invasive pneumococcal di-
sease (IPD) caused by vaccine serotypes in low- and high-risk 
populations [6, 7]. Of the 135 countries that introduced PCV 
by 2016, 69% implemented PCV13, 22% PCV10, and 8% are 
offering both [8]. In low-income countries this pattern is sim-
ilar (76% use PCV13 and 23% PCV10), but the actual number 
of supplied doses of PCV10 and PCV13 is comparable due to 
different population sizes [2].
Because countries with the highest burden of childhood 
pneumococcal disease in general also have the lowest national 
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budgets, the decisive factor on PCV implementation and which 
vaccine to introduce may often be based on costs. Where avail-
able, epidemiological data including the prevalence of serotypes 
causing severe disease should also be considered. Compared to 
countries of low endemicity, the spectrum of pneumococcal 
serotypes causing severe disease is broader in highly endemic 
settings, and the proportion of disease that can be prevented by 
the 2 PCVs is therefore lower [9].
Empirical data on the comparative safety, short-term and 
longer-term immunogenicity, and impact on bacterial carriage 
(and hence potential herd protection) of the 2 vaccines are miss-
ing for highly endemic settings. As it is important to understand 
the performance of these vaccines in such settings to inform 
PCV selection, we conducted a randomized controlled trial, 
studying head-to-head the impact of 3 doses of PCV10 and 
PCV13 administered at 1, 2, and 3 months of age to infants in 
Papua New Guinea (PNG), who, given an estimated IPD inci-
dence rate of 4762/100 000 in the first year of life (2005–2008), 
have one of the highest risks for severe pneumococcal disease 
in the world [10]. With support from GAVI (Global Alliance 
for Vaccines and Immunization), PNG introduced PCV13 in 
2014, but vaccine was not available in the study area until 2015 
and has been introduced slowly since, with coverage for 1 dose 
around 25% and 3 doses around 5% in late 2015 [11].
MATERIALS AND METHODS
Study Design
The trial consisted of 2 parts. The primary objectives of the 
first part (reported here) included assessing safety, immuno-
genicity and antibody persistence after PCV10 or PCV13 vac-
cination at 1, 2, and 3 months of age during the first 9 months 
of life in PNG infants. A secondary objective was to assess car-
riage of pneumococcal vaccine and nonvaccine serotypes, and 
NTHi. The second part of this study aims to assess in PCV10- 
and PCV13-primed PNG infants the safety and immuno-
genicity of 1 dose of pneumococcal polysaccharide vaccine 
(PPV) administered at 9 months of age (not reported here).
A detailed protocol has been published, describing the trial 
aims, objectives, design, study population, and methods includ-
ing consenting procedures [12].
The study was conducted according to Declaration of 
Helsinki International Conference on Harmonisation Good 
Clinical Practice (ICH-GCP) and local ethical guidelines. 
Ethical approval was obtained from the PNG Medical Research 
Advisory Committee (11.03) and PNG Institute of Medical 
Research (PNGIMR) Institutional Review Board (1028). The 
study is registered with ClinicalTrials.gov (CTN NCT01619462).
Study Population
To be eligible for enrolment, children had to be between 28 
and  35  days old, reside within 1 hour’s drive from Goroka 
town, and the family had to intend remaining in the study area 
for 2 years. Exclusion criteria were birth weight <2000 grams; 
severe congenital abnormality; mother or child positive for 
human immunodeficiency virus; or did not provide consent. 
A  total of 262 infants were enrolled between November 2011 
and April 2014.
Randomization and Masking
Infants were randomised 1:1 to receive 3 doses of PCV10 or 
PCV13 using a computer-generated random number list [12]. 
Throughout the study, laboratory staff was blinded to the vac-
cine allocation.
Study Vaccines
PCV10 (Synflorix®, GSK, Belgium, batches ASPNA0099AB, 
ASPNA267DD) contains pneumococcal serotypes 1, 4, 5, 6B, 
7F, 9V, 14 and 23F polysaccharide conjugated to NTHi Protein 
D, and serotypes 18C and 19F polysaccharide conjugated to tet-
anus and diphtheria toxoids, respectively. PCV13 (Prevenar13®, 
Pfizer, USA, batch numbers F36226, G71540) contains pneu-
mococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 
and 23F conjugated to nontoxic diphtheria CRM197 protein.
Study Procedures and Specimen Collection
Prior to any vaccination, the child’s medical history was 
assessed, and a physical examination was performed to exclude 
contraindications for vaccination. PCV10 and PCV13 were 
administered together with routine childhood vaccine [12].
Venous blood samples (3–5 mL) and nasopharyngeal swabs 
(NPS) were collected at 1, 4 and 9 months of age.
Immunogenicity Assessment
Serum Immunoglobulin G (IgG) antibodies against PCV13 
serotypes, and non-PCV serotype 2 were measured using a 
WHO standardized pneumococcal enzyme-linked immuno-
sorbent assay (ELISA) [13, 14] established earlier at PNGIMR 
[10], using the human pneumococcal standard reference serum 
007sp [15] and 10  μg/mL cell wall polysaccharide (CPS) and 
5  μg/mL of purified of serotype 22F polysaccharide for pre-
absorbance of samples to remove nonspecific antibodies and 
increase the specificity of the assay [13]. IgG-serotype-specific 
geometric mean concentrations (GMCs) and the proportion of 
children with concentrations ≥0.35μg/mL (considered the sero-
logical correlate of protection against IPD) were calculated for 
each time point [16].
Reactogenicity and Safety Assessment
Children were observed for 1 hour and visited at home 24–48 
hours post-vaccination to assess local or systemic side effects. 
Children were followed for illness through passive surveillance 
throughout the study [12].
A serious adverse event (SAE) was defined as any event 
requiring hospitalisation or resulting in death. As there were 
disruptions of hospital services in Goroka in 2015, illnesses 
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deemed serious enough to require hospitalisation but managed 
as outpatients were documented as SAEs in this period.
Bacteriology
Pneumococcal and NTHi carriage were assessed using stan-
dard bacteriological culture, isolation, and identification meth-
ods [17]. The Quellung reaction (antisera from Statens Serum 
Institut, Denmark) was used to serotype 2 distinct colonies 
of pneumococci picked from the primary plate. Presumptive 
colonies of H.  influenzae were subcultured and confirmed to 
be H.  influenzae based on their X- and V- factor dependence 
for growth. NTHi were confirmed based on their smooth col-
ony phenotype, whereas typeable H.  influenzae colonies were 
mucoid and were serotyped using H.  influenzae agglutinating 
antisera a-f (Remel, Thermo Fisher Scientific, Australia).
Statistical Methods
A sample size calculation is provided in the published methods 
paper [12].
Data were analyzed based on an intention-to-treat analy-
sis using SPSS 15.0. Antibody concentrations were log-trans-
formed. For continuous variables, differences between groups 
were tested using the 2 sample t-test, and differences within 
individuals over time using paired t-tests. For categorical vari-
ables, differences between groups were tested using Pearson χ2 
test. For all analyses, test outcomes were considered to be sig-
nificantly different if the P-value was ≤.05.
RESULTS
Study Population
Population characteristics were similar for infants randomized 
to the PCV10 or PCV13 group, as reported previously [12]. In 
sum, 90% (118/131) of children in the PCV10 group and 83% 
(109/131) in the PCV13 group completed vaccination accord-
ing to protocol. Follow-up until 9 months of age was completed 
by 108 (82%) children in the PCV10 group and 100 (76%) chil-
dren in the PCV13 group (Figure 1).
Rates of Seroprotection
At 4  months of age, at least 77% of infants had IgG concen-
trations ≥0.35 µg/mL against any serotype for which they had 
been vaccinated (Table 1). For 8/10 shared PCV10/13 serotypes 
IgG concentrations ≥0.35  µg/mL persisted in more than 77% 
of children at 9 months of age. For serotype 1 seroprotection 
rates were significantly higher (P = .006), and for serotype 18C 
significantly lower (P = .041) in the PCV13 than PCV10 group 
at 9 months. Unexpectedly, only 33% of children in the PCV13 
group had IgG concentrations ≥0.35 µg/mL for PCV13 serotype 
3 at 9 months of age, compared to 51% of children in the PCV10 
group (P = .010).
For a higher cutoff value of ≥1.0 μg/mL, predicting longer-term 
protection, rates are presented in Supplementary Table  1. At 
9 months, the highest positive rates were found for serotypes 14 
and 19F (more than 74% positive in either group) and the lowest 
rates for serotypes 4, 9V, and 23F (between 13% and 21% positive 
in either group), and serotype 3 in the PCV13 group (7%).
Serotype-specific IgG GMCs in PCV10- and PCV13-vaccinated Children
IgG GMCs against a number of shared PCV10/13 serotypes dif-
fered between PCV10 and PCV13 vaccinated children, albeit 
not in a consistent pattern, including higher serotype 7F, 19F, 
and 23F IgG GMCs at 4 months, and higher serotype 1, 5, and 
7F IgG GMCs and lower serotypes 6B, 18C, and 19F IgG GMCs 
at 9 months in the PCV13 than in the PCV10 group (P < .05) 
(Table 1 and Figure 2).
IgG responses waned between 4 and 9 months of age by 50% 
to 80% for most vaccine serotypes in both groups, except for 
serotype 14 (15% waning) in the PCV13 group, and serotypes 
19F (20% waning) and 6B (no decline) in the PCV10 group 
(Figure 3 and Supplementary Table 2).
Reactogenicity, Safety, and Morbidity
Reactogenicity was moderate, with no differences other than 
more redness at the injection site after the first dose of PCV10 
(12%) compared to PCV13 (5%) (P  =  .040) (Supplementary 
Table 3).
A total of 438 illness episodes were documented during the 
8 month follow-up period. No vaccine-related SAEs occurred. 
Incidence rates of all-cause morbidity and moderate/severe 
pneumonia tended to be higher between 1 and 4 months of age 
than between 4 and 9  months of age (Table  2). Three infants 
developed IPD, including 1 infant developing severe pneumo-
nia at 8 weeks of age after 1 dose of PCV13 (serotype 7F cultured 
from blood); 1 infant developing pneumococcal meningitis at 
10 weeks of age after 2 doses of PCV10 (serotype 8 cultured 
from CSF); and 1 infant developing pneumococcal sepsis at 12 
weeks of age after 3 doses PCV10 (serotype 46 cultured from 
blood). There were no significant differences in incidence rates 
of any illness, hospitalization, ALRI, or moderate/severe ALRI 
between the PCV10 and PCV13 groups.
Pneumococcal and NTHi Carriage
At 1 month of age, 65% (95% confidence interval [CI] 58.4%–
70.3%) of infants were pneumococcal carriers (Table 3): 34.4% 
(95% CI 28.6–40.4) carried nonvaccine serotypes, 14.9% (95% CI 
10.8–19.8) nonserotypeable pneumococci, 14.9% (95% CI 10.8–
19.8) any of the shared PCV10/13 serotype, and 3.1% (95% CI 
1.3–5.9) any of the 3 additional PCV13 serotypes. At 4 months, 
92% of children in the PCV10 group and 81% in the PCV13 group 
were pneumococcal carriers (P = .023), and at 9 months carriage 
rates were 88% and 90% in the PCV10 and PCV13 group, respec-
tively (P > .05). Carriage of any shared PCV10/13 serotypes was 
comparable between the groups at 4 or at 9 months of age.
A total of 65 different colonizing pneumococcal serotypes 
were identified during the study period, already 49 at 1 month 
of age (Supplementary Table  4). Serotype 23F was the most 
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frequently carried serotype at 1 and 4 months of age and sero-
type 19A at 9  months. Carriage of nonserotypeable pneumo-
cocci was common: (21.7%, 14.6%, and 9.5% of pneumococcal 
isolates at 1, 4, and 9 of age, respectively) (Table 3).
NTHi was carried by 41.3% (95% CI 35.1–47.6) of infants at 
1 month of age. At 4 and 9 months carriage rates were 69.4% 
and 53.3% in the PCV10 group, respectively, and 58.8% and 
57.1% in the PCV13 group, respectively (Table 3).
DISCUSSION
Because the epidemiology of pneumococcal infections differs 
with the level of endemicity, studies in highly endemic settings 
are important to understand the impact and possible limitations 
of PCVs in these environments. In this head-to-head study in a 
highly endemic setting in PNG, both PCV10 and PCV13 were 
found to be immunogenic and well tolerated when given at the 
accelerated national schedule of 1, 2, and 3 months of age. More 
than 90% of infants had seroprotective antibody levels against 
most vaccine serotypes at 4  months of age, which is import-
ant considering the high incidence of IPD in young infants in 
highly endemic settings like PNG.
Overall, antibody levels waned rapidly between 4 and 
9 months of age. A booster dose of PCV in later infancy may 
help to sustain protective levels but may be too expensive to 
implement in low-income countries. Whether a 2  +  1 sched-
ule, as implemented in several low-risk countries, is effective in 
high-risk settings where there is early onset of dense carriage 
and the incidence of IPD in young infants is high, has yet to be 
determined [18]. An alternative is to complement priming with 
3 doses of PCV with 1 dose of 23-valent polysaccharide vaccine 
Figure 1. Flowchart. HIV, human immunodeficiency virus; LTFU, lost to follow-up; Mig, Migration; PCV10, 10-valent pneumococcal conjugate vaccine; PCV13, 13-valent 
pneumococcal conjugate vaccine; PV, protocol violation; WC, withdrawn consent.
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(PPV). This approach was used in Australia to increase sero-
type coverage in high-risk Aboriginal children but was halted 
after suggestions that PPV may deplete serotype-specific mem-
ory B-cells [19]. In an earlier study where PNG infants received 
PPV after priming with PCV7, there was no evidence of hypo-
responsiveness [20], and this strategy will be further studied in 
the follow-up of this study.
In addition to preventing IPD, PCV immunization can pre-
vent colonization, which can lead to herd protection in the 
nonvaccinated population due to reduced circulation of vaccine 
serotypes. In contrast to low and moderately endemic settings, 
there is evidence that in high-risk settings the impact of PCVs 
on preventing carriage is limited [21, 22]. Possible explanations 
are that in high-risk populations the density of colonization is 
too high to allow complete clearance, or that antibodies are of a 
low avidity and lack opsonophagocytic activity. The latter may 
also explain why naturally acquired maternal antibodies despite 
high titers do not protect infants in high-risk settings from 
pneumococcal colonization [23]. To optimize the effectiveness 
and full potential of PCVs in high-risk settings, more studies in 
Figure 3. GM fold change in PCV-induced IgG responses between 4 and 9 months 
of age. GM fold changes and 95% CIs in vaccine-induced IgG antibody titers 
between 4 and 9 months of age were calculated for shared PCV10/13 serotypes 
for both PCV10- (orange square) and PCV13- (blue circle) vaccinated children, as 
well as for PCV13-only serotypes (*) for the PCV13-vaccinated group. GMs and 95% 
CIs < 1 correspond to a significant (P < .05) decline in antibody responses. GM 
fold changes were compared between the groups for each shared vaccine serotype 
using a 2-sample t-test and when a significant difference was found P-values were 
included. Abbreviations: CI, confidence interval; GM, geometric mean; IgG, immu-
noglobulin G; PCV, pneumococcal conjugate vaccine.
Figure 2. GMCs of serotype-specific IgG antibodies. GMCs and 95% CIs for IgG antibodies against shared PCV10/13 serotypes, (*) PCV13-only serotypes, and (**) non-PCV 
serotype 2 measured before vaccination, at 4 months of age, and at 9 months of age were compared between children vaccinated with either three doses of PCV10 (orange 
square) or PCV13 (blue circle) using a 2-sample t-test and indicated with (#) when significantly different (P < .05). Abbreviations: CI, confidence interval; GMC, geometric mean 
concentration; IgG, immunoglobulin G; PCV, pneumococcal conjugate vaccine.
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these settings are required to understand the impaired impact on 
pneumococcal colonization, how this may be achieved (eg, PCV 
booster doses), what a possible impact on carriage load could 
mean in terms of inducing herd protection, and what the effect is 
on serotype-specific versus non-serotype-specific carriage load, 
considering findings of increased overall pneumococcal carriage 
load in PCV-vaccinated compared to unvaccinated children in 
settings of dense and diverse carriage [24, 25].
Children in high-risk settings experience pneumococcal 
colonization from a very young age. For example, in the high-
lands of PNG infants are colonized with pneumococcus at a 
median age of 17–18  days [26]. This increases their risk of 
developing pneumococcal disease and may negatively af-
fect PCV responses [27, 28]. In settings where colonization 
occurs so early, starting immunization as early as possible 
may therefore improve PCV’s immunogenicity and protec-
tion against IPD in early life. Studies in PNG and Kenya have 
demonstrated that neonatal vaccination with PCV7 is safe 
and does not compromise immunogenicity [10, 22]. Neonatal 
vaccination also has the potential of increasing vaccine up-
take, particularly in settings where most women give birth in 
clinics or health centres.
Given the diversity of serotypes with the potential of causing 
disease carried by infants in high-risk settings (65 serotypes in 
this study), the coverage afforded by current PCVs is limited 
(<50% of IPD serotypes for PCV13 in PNG). However, because 
the overall incidence of pneumococcal disease in high-endemic 
settings is high, routine immunization with PCV10 or PCV13 
can still be expected to prevent significant morbidity and mor-
tality due to vaccine serotypes and be cost-effective [29].
A limitation of conducting a field trial as intensive as this one under 
challenging logistical conditions and with limited funding is that the 
size of the cohort that can be studied is restricted. As carriage rates of 
vaccine serotypes in the population were lower than predicted, a larger 
Table 3. Proportion of Children Colonized With Streptococcus pneumoniae (Pnc) and/or Nontypeable Haemophilus influenzae (NTHi) Before and After 
Vaccination With 3 Doses of 10-valent Pneumococcal Conjugate Vaccine (PCV10) or 10-valent Pneumococcal Conjugate Vaccine (PCV13)
Age 1 Month
(Before Vaccination)
Age 4 Months
(1 Month Postvaccination)
Age 9 Months
(6 Months Postvaccination)
PCV10
(n = 131)
PCV13
(n = 131) P-Value
PCV10
(n = 111)
PCV13
(n = 102) P-Value
PCV10
(n = 98)
PCV13
(n = 105) P-Value
Any Pnc 63.4%
(54.5–71.6)
65.6%
(56.9–73.7)
.699 91.9%
(85.2–96.2)
81.4%
(72.4–88.4)
.023 87.6%
(79.8–93.2)
89.8%
(82.0–95.0)
.625
PCV10/13  
serotypes
13.0%
(7.7–20.0)
16.8%
(10.8–24.3)
.386 25.5%
(17.6–34.6)
18.6%
(11.6–27.6)
.232 19.0%
(12.0–27.9)
13.4%
(7.3–21.8)
.278
PCV13 only  
serotypes
1.5%
(0.2–5.4)
4.6%
(1.7–9.7)
.281 9.1%
(4.4–16.1)
5.9%
(2.2–12.4)
.377 14.3%
(8.2–22.5)
8.2%
(3.6–15.6)
.177
Nonvaccine  
serotypes
38.9%
(30.5–47.8)
29.8%
(22.1–38.4)
.119 52.7%
(43.0–62.3)
45.1%
(35.2–55.3)
.267 56.2%
(46.2–65.9)
59.8%
(49.3–69.6)
.604
Nonserotypeable  
Pnc
10.7%
(6.0–17.3)
19.1%
(12.7–26.9)
.056 15.5%
(9.3–23.6)
22.5%
(14.9–31.9)
.187 6.7%
(2.7–13.3)
12.4%
(6.6–20.6)
.165
NTHi 44.0%
(35.1–53.2)
38.6%
(30.1–47.6)
.383 69.4%
(59.9–77.8)
58.8%
(48.6–68.5)
.109 53.3%
(43.3–63.1)
57.1%
(46.7–67.1)
.586
Proportion and 95% confidence intervals of children carrying any pneumococcus; shared PCV10/13 serotypes; PCV13-only serotypes; nonserotypeable pneumococci; and NTHi at different 
time points before and after vaccination with three doses of PCV10 or PCV13. Differences between groups were tested using Pearson χ2 test.
Abbreviations: NTHi, Haemophilus influenzae; PCV, pneumococcal conjugate vaccine; Pnc, Streptococcus pneumoniae.
Table  2. Incidence Rates of Any Morbidity, Hospitalization, and Any or Moderate/Severe Acute Lower Respiratory Tract Infections (ALRI) 
According to Age
Age
PCV10 PCV13
P-ValueEvents Incidence per Person-Year (95% CI) Events Incidence per Person-Year (95% CI)
1–3 months Any morbidity 94 3.14 (2.56–3.84) 97 3.37 (2.77–4.12) .616
Any hospitalization 12 0.40 (0.23–0.71) 9 0.31 (0.16–0.60) .576
Moderate/Severe ALRI 19 0.63 (0.40–0.99) 13 0.45 (0.26–0.78) .347
Any ALRI 35 1.17 (0.84–1.63) 34 1.18 (0.85–1.66) .960
4–9 months Any morbidity 129 2.42 (2.04–2.88) 118 2.27 (1.90–2.72) .617
Any hospitalisation 17 0.32 (0.20–0.51) 13 0.25 (0.15–0.43) .510
Moderate/Severe ALRI 27 0.51 (0.35–0.74) 19 0.37 (0.23–0.57) .276
Any ALRI 63 1.18 (0.92–1.51) 51 0.98 (0.75–1.29) .324
The table shows the number of events and incidence rates (with 95% confidence intervals) of any illness, hospitalization, and acute lower respiratory tract infections (ALRI) between 1 and 
3 months of age, and between 4 and 9 months of age in infants vaccinated with 3 doses of PCV10 or PCV13. Differences between groups were tested using Pearson χ2 test.
Abbreviations: ALRI, acute lower respiratory tract infections; CI, confidence interval; PCV, pneumococcal conjugate vaccine.
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sample size would have been needed to show an impact, if any, on 
vaccine serotype carriage. However, the study had sufficient power to 
study the safety, immunogenicity, and suitability to immunize infants 
with the available PCVs in this high-risk setting. Despite the high 
mobility of this population, almost 80% of children were followed up 
to 9 months of age, with nasopharyngeal and serum samples collected 
from nearly all children (>97%, involving more than 1100 visits). The 
success of this study is a reflection of the long-established relationship 
and trust between the community and PNGIMR staff, and the perse-
verance of field staff in locating participants.
PCV13 was introduced in PNG in a 3 + 0 schedule in 2014. 
Uptake has been slow, and it will take time before its impact 
can be assessed. Establishing a surveillance program in PNG 
to monitor the impact of PCV13 implementation on IPD and 
possible change in serotypes causing disease is important. The 
impact of PCV13 implementation on herd protection is cur-
rently being investigated in the highlands of PNG as part of a 
multicentre study (PneuCAPTIVE study [30]).
In summary, this head-to-head study shows that PCV10 and 
PCV13 are comparably safe and immunogenic and are suitable 
to immunize infants in a high-risk setting. Considerations by 
high-risk countries on which PCV to introduce will therefore 
depend on the local IPD epidemiology, pricing differences, and 
vaccine availability. The impact of either PCV on IPD may be 
less in a high endemicity setting than low endemicity setting 
due to (i) limited coverage of serotypes causing disease; (ii) less 
effect on vaccine serotype carriage, which constrains herd pro-
tection; and (iii) faster waning of antibody responses. Further 
studies are needed to better understand and optimize the 
potential of PCVs in these settings, including the use of booster 
vaccinations and accelerated schedules. Next generation PCVs 
are in development with different serotype compositions for use 
in low-income settings; these will need to be evaluated in high 
incidence settings to understand and maximize their impact.
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